These results suggest that β2M silencing downregulated p-SGK1/SGK1 levels and Bcl-2 expression, but did not affect the HER2, HIF-1α, VEGF and ERK signaling in ER+ breast cancer cells with HER2−. The gene discussed is ERBB2; the disease is breast carcinoma.